Dame Louise Makin elected to Avantor board of directors

Avantor, Inc.

Elected November 4, 2024 as independent director; term expires at 2025 Annual Meeting.
Former CEO of BTG plc (2004-2019), led transformation and $4.2B sale to Boston Scientific.
Currently non-executive chair of Halma plc, a FTSE 100 life-saving technology group.
Standard non-employee director compensation: $95k annual cash, $210k RSU grant (both prorated for 2024), plus $15k tax stipend.
Fills a vacant Board seat; Board determined she meets NYSE and Exchange Act independence standards.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dame Louise Makin DBE

director

AVTR · Avantor, Inc.

Effective: 2024-11-04
Filed: November 6, 2024, 6:59 PM ET

On November 4, 2024, the Board of Directors (the “Board”) of Avantor, Inc. (the “Company”), upon the recommendation of its Nominating and Governance Committee, elected Dame Louise Makin DBE as a director with an initial term expiring on the date of the Company’s 2025 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dame Louise Makin DBE was elected as director at Avantor, Inc..

Action: elected
Role: director

Exact text from the filing

On November 4, 2024, the Board of Directors (the “Board”) of Avantor, Inc. (the “Company”), upon the recommendation of its Nominating and Governance Committee, elected Dame Louise Makin DBE as a director with an initial term expiring on the date of the Company’s 2025 Annual Meeting of Stockholders.

View on SEC.gov

Avantor, Inc. filing history →

Source: SEC EDGAR

accession 0001722482-24-000171

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.